Insights & Perspectives

Filter by














Therapeutic Area / Research

Search Insights:
Showing 1 to 10 of 145
Filter by: Article

Article | Jul 16, 2019

Three Key Questions About Adherence/Compliance in 2019

Read more | | Share

Article | Jun 4, 2019

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019.

Read more | | Share

Article | Jun 4, 2019

ASCO 2019 – phase I data generates hope for the future

Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS inhibitor AMG 510. Arnold DuBell, a senior consultant at Kantar, discusses further.

Read more | | Share

Article | Jun 3, 2019

ASCO 2019 – Enfortumab comes out fighting in bladder cancer

At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastatic bladder cancer. The data presented were from Cohort 1 of the trial, which evaluated enfortumab in relapsed patients who had been treated with a platinum and a checkpoint inhibitor. Kantar’s Len Kusdra reviewed the study.

Read more | | Share

Article | Jun 3, 2019

ASCO 2019 – The results of clinical practice changing phase III studies

At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase III studies, but the future is also here. Early phase I and II trials that test new molecules are also a highlight of the congress and many of these studies are presented in smaller sessions. Kantar’s Otavio Clark commented on two of these studies, that have the potential to improve the care of patients.

Read more | | Share

Article | Jun 2, 2019

ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial

There were a number of noteworthy outcomes from the KEYNOTE-062 trial that was presented on day two of ASCO 2019 in Chicago. The study looked at Merck & Co’s Keytruda as a first-line treatment for gastric cancer, and prompted questions about the meaningfulness of non-inferiority. Kantar’s Debbie Warner and Michael Gaschler debated the results.

Read more | | Share

Article | Jun 2, 2019

ASCO 2019 – Kantar reviews multiple myeloma showdown

Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen’s Darzalex and Sanofi’s isatuximab. Kelly Clapp from Kantar reviewed the data from the multiple myeloma showdown and provides some thoughts on what it means for the therapy area.

Read more | | Share

Article | Jun 2, 2019

ASCO 2019 – Kantar reviews results from phase 3 POLO trial

Anna Boudoures from Kantar reviewed the “practice-changing” results of the phase 3 POLO trial of AstraZeneca and Merck & Co’s drug, as presented at ASCO 2019 in Chicago.

Read more | | Share

Article | May 31, 2019

ASCO 2019 – Kantar takes a first look at interim data from the phase 3 TITAN trial

Megan Epperson closed out the first day of ASCO 2019 with a look at interim data from the phase 3 TITAN trial.

Read more | | Share

Article | Apr 29, 2019

Patient Journeys

Read more | | Share
Page  < 12345678910 >